The CD133 <sup>+</sup> Cell as Advanced Medicinal Product for Myocardial and Limb Ischemia
Dario Bongiovanni(Augsburg University), Giulio Pompilio(University of Milan), Corrado Carbucicchio(Centro Cardiologico Monzino), Elisa Gambini(Centro Cardiologico Monzino), Paolo Scacciatella(University of Turin), Giacomo Frati(Istituto Neurologico Mediterraneo), Beatrice Bassetti(Centro Cardiologico Monzino), Giuseppe Gaipa(University of Milano-Bicocca), Felice Achilli(Azienda Ospedaliera San Gerardo)
Cited by 25
Related Papers
European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism
|European Heart Journal|2018|435
Endo-Epicardial Homogenization of the Scar Versus Limited Substrate Ablation for the Treatment of Electrical Storms in Patients With Ischemic Cardiomyopathy
|Journal of the American College of Cardiology|2012|423
Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy
|Journal of the American College of Cardiology|2015|341
Coronary computed tomography angiography for heart team decision-making in multivessel coronary artery disease
|European Heart Journal|2018|243
Pro-Angiogenic Macrophage Phenotype to Promote Myocardial Repair
|Journal of the American College of Cardiology|2019|194